Zhitong Finance APP News, Hengrui Pharmaceutical (600276crashteamracingnitrofueledps4.SH) issued an announcement that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.crashteamracingnitrofueledps4SHR-A1921 for injection is planned to be included in the publicity list of breakthrough treatment varieties by the Center for Drug Evaluation of the State Food and Drug Administration, with a publicity period of 7 days. Proposed indications (or functions) for this drugcrashteamracingnitrofueledps4: Used for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.